Mainz Biomed Raises $4 Million in Follow-On Offering for Cancer Detection

Mainz Biomed announced a follow-on offering of 2 million units, raising approximately $4 million for cancer detection initiatives.

Offering Details and Structure

Mainz Biomed N.V. has priced a follow-on offering of 2,000,000 units. Each unit consists of one ordinary share (or pre-funded warrant), one Series A warrant, and one Series B warrant. This offering is expected to yield gross proceeds of about $4.0 million at an effective price of $2.00 per unit. The offering is anticipated to close on or about May 21, 2025, contingent on customary conditions. Maxim Group LLC is the sole placement agent for this transaction. Additionally, the company is amending previously issued warrants to reduce their exercise price to $2.00. This offering is conducted under a registration statement recently deemed effective by the SEC. Mainz Biomed focuses on molecular genetic diagnostics for cancer detection, including products like the ColoAlert® test for colorectal cancer and the PancAlert test for early-stage pancreatic cancer screening.

Potential Advantages

• This follow-on offering provides $4 million, supporting the company’s operations and developmental initiatives.
• The inclusion of Series A and Series B warrants may draw further investment interest and potentially increase shareholder value, as they are immediately exercisable at $2.00.
• Reducing the effective strike price for previously issued warrants could enhance their appeal for investors and improve the company’s liquidity.

Potential Challenges

• Offering units at an effective price of $2.00 may indicate a lack of investor confidence, reflecting a lower valuation for the company’s shares.
• The adjustment in exercise prices for previously issued warrants could suggest pressure on stock performance, possibly diluting existing shareholder value.
• Forward-looking statements indicate risks and uncertainties, including potential impacts from COVID-19, which may weaken investor confidence in the company’s future.

Frequently Asked Questions

What is the recent offering by Mainz Biomed?

Mainz Biomed announced a follow-on offering of 2,000,000 units for gross proceeds of approximately $4.0 million.

What does each unit in the offering consist of?

Each unit includes one ordinary share, one Series A warrant, and one Series B warrant.

What is the exercise price for the Series A and Series B warrants?

Both Series A and Series B warrants have an exercise price of $2.00 per share.

When is the closing date for this offering?

The offering is expected to close on or about May 21, 2025, subject to closing conditions.

How can investors obtain the final prospectus for this offering?

Copies of the final prospectus may be obtained from Maxim Group LLC at their New York office.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes.

$MYNZ Hedge Fund Activity

Currently, there have been no institutional investors adding shares of $MYNZ, while two have decreased their positions in the most recent quarter.

• CITIGROUP INC removed 17 shares (-100.0%) from their portfolio in Q4 2024, valued at approximately $73
• MORGAN STANLEY removed 5 shares (-100.0%) from their portfolio in Q4 2024, valued at approximately $21

Full Release

BERKELEY, Calif. and MAINZ, Germany, May 19, 2025 (GLOBE NEWSWIRE) —

Mainz Biomed N.V. (NASDAQ:MYNZ)

(“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company focusing on early cancer detection, today announced the pricing of a follow-on offering consisting of 2,000,000 units. Each unit will include one ordinary share (or a pre-funded warrant in its place), alongside one Series A warrant and one Series B warrant, each being sold at an effective price of $2.00 per unit. Each Series A warrant will be immediately exercisable at $2.00 per share, expiring five years from issuance. Each Series B warrant will also be immediately exercisable at $2.00 per share and will expire upon the earlier of 30 days following results from the Company’s eAArly Detect 2 study or one year from issuance.

Maxim Group LLC serves as the sole placement agent for this offering, which is projected to close on or about May 21, 2025, subject to customary closing conditions.

The Company has also executed a Warrant Amendment Agreement to lower the effective strike price of existing Series A and Series B Warrants issued on December 12, 2024. The amended exercise price for these outstanding warrants will be set at $2.00.

The newly issued securities are being offered under a registration statement on Form F-1, as amended (File No. 333-287249), which the SEC declared effective on May 16, 2025. The offering will only be conducted through a prospectus that is part of the Registration Statement. A final prospectus related to this offering will be submitted to the SEC, and copies can be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745.

This press release does not constitute a sale offer of any of the securities described herein, nor a solicitation for an offer to buy such securities in any jurisdiction where such actions would be unlawful prior to the required registration under relevant securities laws.

For more investor information, visit Mainz Biomed’s official investor site.

About Mainz Biomed NV

Mainz Biomed develops molecular genetic diagnostic solutions for serious medical conditions. Its flagship product, ColoAlert®, is a non-invasive test for early detection of colorectal cancer, marketed across Europe. The company is currently preparing for pivotal FDA clinical studies to obtain US regulatory approval and has a robust product candidate portfolio.